1 completed. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow PSP: new trials by email Literature Review of PSP trials Research Report on PSP
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMX0035 and Progressive Supranuclear Palsy AMX0035, Placebo - Progressive Supranuclear Palsy, PSP | Phase 2 / Phase 3 | Completed | Amylyx Pharmaceuticals Inc. | 139 | 2023-12-21 | 2026-04-30 |
Neurodegenerative Diseases (1) · Supranuclear Palsy, Progressive (1)
Basal Ganglia Diseases (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cranial Nerve Diseases (1) · Eye Diseases (1) · Movement Disorders (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Ocular Motility Disorders (1) · Ophthalmoplegia (1) · Paralysis (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Tauopathies (1)
sodium phenylbutyrate and taurursodiol (1)
Amylyx Pharmaceuticals Inc. (1)
France (1) · Germany (1) · Italy (1) · Spain (1) · United States (1)